Utilisation des immunoglobulines intraveineuses au cours de la sclérodermie systémique : étude rétrospective multicentrique
Sébastien Sanges(Inserm), David Launay(Inserm), É. Hachulla(Centre Hospitalier Universitaire de Lille), Alban Deroux(Centre Hospitalier Universitaire de Grenoble), Emmanuel Chatelus(Laboratoire National de Référence), A. Mékinian(Sorbonne Université), Alain Lescoat(Inserm), Thierry Martin(Western Infirmary), T. Quéméneur(Centre Hospitalier de Valenciennes), A. Le Quellec(Centre Hospitalier Universitaire de Montpellier), Pierre‐Yves Hatron(Centre Oscar Lambret), Sébastien Rivière(Sorbonne Université)
Cited by 0
Related Papers
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432